Research ArticleBasic Science Investigations
Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Oliver S. Grosser, Frank Osterkamp, Annette Pethe, Ulrich Reineke, Christiane Smerling and Holger Amthauer
Journal of Nuclear Medicine July 2016, 57 (7) 1120-1123; DOI: https://doi.org/10.2967/jnumed.115.170530
Jörg Schulz
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
Martin Rohracker
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
Marvin Stiebler
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
Jürgen Goldschmidt
2Leibniz-Institut für Neurobiologie, Magdeburg, Germany
Oliver S. Grosser
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
Frank Osterkamp
33B Pharmaceuticals GmbH, Berlin, Germany; and
Annette Pethe
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
Ulrich Reineke
33B Pharmaceuticals GmbH, Berlin, Germany; and
Christiane Smerling
33B Pharmaceuticals GmbH, Berlin, Germany; and
Holger Amthauer
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany
4Department of Nuclear Medicine, Charité–Universitätsmedizin, Berlin, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Oliver S. Grosser, Frank Osterkamp, Annette Pethe, Ulrich Reineke, Christiane Smerling, Holger Amthauer
Journal of Nuclear Medicine Jul 2016, 57 (7) 1120-1123; DOI: 10.2967/jnumed.115.170530
Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Oliver S. Grosser, Frank Osterkamp, Annette Pethe, Ulrich Reineke, Christiane Smerling, Holger Amthauer
Journal of Nuclear Medicine Jul 2016, 57 (7) 1120-1123; DOI: 10.2967/jnumed.115.170530
Jump to section
Related Articles
Cited By...
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
- NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics
- Citius, Altius, Fortius: An Olympian Dream for Theranostics